Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 6/20 | 0.48 |
| ▸ | CA1 | P00915 | 6/20 | 0.48 |
| ▸ | CA2 | P00918 | 6/20 | 0.48 |
| ▸ | CA9 | Q16790 | 6/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 3/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 2/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7076188 | 0.97 | CA12 (0.48) | CA12CA1CA2CA9FFAR1 | |
| SCHEMBL7075078 | 0.96 | CA12 (0.48) | CA12CA1CA2CA9FFAR1 | |
| SCHEMBL7072137 | 0.95 | CA12 (0.47) | CA12CA1CA2CA9BRD4 | |
| SCHEMBL7071687 | 0.94 | CA12 (0.47) | CA12CA1CA2CA9FFAR1 | |
| SCHEMBL7073944 | 0.94 | CA12 (0.48) | CA12CA1CA2CA9FFAR1 | |
| SCHEMBL7075211 | 0.92 | CA12 (0.46) | CA12CA1CA2CA9BRD4 | |
| SCHEMBL7071440 | 0.91 | CA12 (0.47) | CA12CA1CA2CA9FFAR1 | |
| SCHEMBL7073139 | 0.91 | CA12 (0.47) | CA12CA1CA2CA9FFAR1 | |
| SCHEMBL7073295 | 0.89 | CA12 (0.45) | CA12CA1CA2CA9FFAR1 | |
| SCHEMBL7075787 | 0.88 | CA12 (0.46) | CA12CA1CA2CA9FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030109523-A1 | Bicyclic antagonists selective for the alphavbeta3 integrin | WYETH (US) | 2003-06-12 | — | — | US | disclosed |
| US-6429214-B1 | INHIBITORS OF BONE RESORPTION | WYETH | 2002-08-06 | — | — | US | disclosed |
| EP-1198231-A1 | BICYCLIC ANTAGONISTS SELECTIVE FOR THE(ALPHA)V(BETA)3 INTEGRIN | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-04-24 | — | — | EP | disclosed |
| WO-2001007036-A1 | BICYCLIC ANTAGONISTS SELECTIVE FOR THE αvβ3 INTEGRIN | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109523-A1 | Bicyclic antagonists selective for the alphavbeta3 integrin | ITGAV, ITGB2, ITGB3 | CA12 4002/4885CA1 2574/4885CA2 3061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.